Gilead Sciences Inc.
Gilead Sciences Reports Strong Q1 2026 Results and Updates Guidance
Summary
Gilead Sciences, Inc. announced its first quarter 2026 financial results, showing an 8% year-over-year growth in product sales excluding Veklury, driven by a 10% increase in HIV product sales and a 37% rise in Trodelvy sales. The company reported total revenues of $7.0 billion, a 4% increase from the same period in 2025. Gilead also declared a quarterly dividend of $0.82 per share and updated its full-year 2026 guidance, reflecting its strong performance.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement